RNA-targeted small-molecule drugs for glioblastoma
Raised to date
$2.3M
of $4M offered across 1 Form D filing
Tinos Therapeutics is a preclinical oncology company developing RNA-targeted cancer therapies. It was spun out of research at Brown University showing that cancer cells depend on the RNA demethylase FTO for survival, and it builds small-molecule inhibitors intended to destabilize tumor-driving RNA. Its lead TN01 series is at the pre-IND stage, aimed at glioblastoma, colorectal cancer, and AML.
Targets RNA methylation rather than the protein or DNA layer, using an AI-assisted EpiCode platform to design first-in-class small-molecule FTO inhibitors.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 17, 2026 | Option to acquire | $2.3M/ $4M | Form D/A |
Preclinical small-molecule oncology program
A pre-IND series of small-molecule inhibitors of the RNA demethylase FTO, designed to destabilize the RNA that drives tumor survival.
Built for
Oncology patients with hard-to-treat tumors (glioblastoma, colorectal cancer, AML), reached via clinicians and pharmaceutical partners
